Reported resultsCompany-reported
What was reported
EMERYVILLE, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today provided business updates and reported its second quarter 2026 financial results.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
What the evidence supports
BioAge Labs published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineBioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Press release lead paragraphEMERYVILLE, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today provided business updates and reported its second quarter 2026 financial results.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.